Valiltramiprosate (ALZ-801)
Early Symptomatic Alzheimer's Disease (APOE4/4 Homozygotes)
Phase 3Active (Trial Completed)
Key Facts
Indication
Early Symptomatic Alzheimer's Disease (APOE4/4 Homozygotes)
Phase
Phase 3
Status
Active (Trial Completed)
Company
About Alzheon
Alzheon is a private, clinical-stage biotech advancing a late-stage, oral therapy for Alzheimer's disease. Its lead candidate, valiltramiprosate (ALZ-801), has completed a pivotal Phase 3 trial (APOLLOE4) targeting high-risk APOE4/4 homozygous patients, with data published in 2025. The company's strategy is based on a precision medicine platform focused on inhibiting neurotoxic soluble amyloid oligomers, a key driver of pathology, and it has been supported by significant non-dilutive funding from the National Institute on Aging.
View full company profile